These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 19261105

  • 1. Pharmacokinetic study of mizoribine in child-onset glomerulonephritis.
    Abe Y, Mikawa T, Fuke T, Hisano M, Tsuji Y, Watanabe S, Itabashi K.
    Pediatr Int; 2008 Oct; 50(5):615-9. PubMed ID: 19261105
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China.
    Xia ZK, Gao YF, Rong LP, Dang XQ, Shen Q, Jiang XY, Yi ZW, Xu H.
    World J Pediatr; 2019 Jun; 15(3):262-269. PubMed ID: 30864060
    [Abstract] [Full Text] [Related]

  • 3. Mizoribine requires individual dosing due to variation of bioavailability.
    Fuke T, Abe Y, Hibino S, Takeshi M, Saito T, Sakurai S, Watanabe S, Murayama J, Itabashi K, Nakano Y.
    Pediatr Int; 2012 Dec; 54(6):885-91. PubMed ID: 23039376
    [Abstract] [Full Text] [Related]

  • 4. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.
    Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, Nishi S, Yoshimura A, Sato H, Ogahara S, Sasatomi Y, Kataoka Y, Ueda S, Koyama A, Maruyama S, Nangaku M, Imai E, Matsuo S, Tomino Y, Refractory Nephrotic Syndrome Study Group.
    Clin Exp Nephrol; 2017 Dec; 21(6):961-970. PubMed ID: 27783276
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of mizoribine in pediatric patients with kidney disease.
    Kaneda H, Shimizu M, Ohta K, Ushijima K, Gotoh Y, Satomura K, Nagai T, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Takaai M, Hashimoto Y, Uemura O.
    Clin Exp Nephrol; 2016 Oct; 20(5):757-763. PubMed ID: 26649561
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.
    Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E.
    Clin Nephrol; 2005 Jun; 63(6):417-22. PubMed ID: 15960142
    [Abstract] [Full Text] [Related]

  • 8. Assessment of factors associated with mizoribine responsiveness in children with steroid-dependent nephrotic syndrome.
    Kondoh T, Ikezumi Y, Yokoi K, Nakajima Y, Matsumoto Y, Kaneko M, Hasegawa H, Yamada T, Kumagai N, Ito T, Yoshikawa T.
    Clin Exp Nephrol; 2019 Sep; 23(9):1154-1160. PubMed ID: 31187341
    [Abstract] [Full Text] [Related]

  • 9. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.
    Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E.
    Pediatr Nephrol; 2006 Jul; 21(7):962-6. PubMed ID: 16773408
    [Abstract] [Full Text] [Related]

  • 10. Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome.
    Utsunomiya Y, Hara Y, Ito H, Okonogi H, Miyazaki Y, Hashimoto Y, Hosoya T.
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):751-5. PubMed ID: 20979934
    [Abstract] [Full Text] [Related]

  • 11. The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease.
    Nagai T, Uemura O, Kaneda H, Ushijima K, Ohta K, Gotoh Y, Satomura K, Shimizu M, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Hashimoto Y.
    Clin Exp Nephrol; 2017 Oct; 21(5):884-888. PubMed ID: 27873037
    [Abstract] [Full Text] [Related]

  • 12. High-dose mizoribine treatment for adolescents with systemic lupus erythematosus.
    Nozu K, Iijima K, Kamioka I, Fujita T, Yoshiya K, Tanaka R, Nakanishi K, Yoshikawa N, Matsuo M.
    Pediatr Int; 2006 Apr; 48(2):152-7. PubMed ID: 16635174
    [Abstract] [Full Text] [Related]

  • 13. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis.
    Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S.
    Clin Nephrol; 2003 Dec; 60(6):390-4. PubMed ID: 14690255
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.
    Takei S.
    Pediatr Int; 2002 Apr; 44(2):205-9. PubMed ID: 11896888
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome].
    Goto M, Ikeda M, Hataya H, Ishikura K, Hamasaki Y, Honda M.
    Nihon Jinzo Gakkai Shi; 2006 Apr; 48(4):365-70. PubMed ID: 16780106
    [Abstract] [Full Text] [Related]

  • 19. Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine.
    Ito T, Mochizuki K, Oka T, Hanada K, Tanabe K.
    Int Urol Nephrol; 2015 Jan; 47(1):131-5. PubMed ID: 25298141
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.